Johnson & Johnson $JNJ Shares Sold by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 95.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,254 shares of the company’s stock after selling 26,755 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Johnson & Johnson were worth $232,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank boosted its holdings in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Versor Investments LP acquired a new position in Johnson & Johnson during the first quarter worth $444,000. Erste Asset Management GmbH grew its stake in shares of Johnson & Johnson by 28.8% during the 1st quarter. Erste Asset Management GmbH now owns 233,107 shares of the company’s stock worth $38,658,000 after purchasing an additional 52,086 shares during the period. Finally, Level Four Advisory Services LLC increased its stake in Johnson & Johnson by 6.1% in the 1st quarter. Level Four Advisory Services LLC now owns 66,662 shares of the company’s stock valued at $11,055,000 after purchasing an additional 3,845 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $210.50 on Thursday. The business has a 50 day moving average price of $197.44 and a two-hundred day moving average price of $178.46. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a market capitalization of $507.14 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 2.27 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JNJ shares. Barclays raised their price objective on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Argus set a $210.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Finally, UBS Group lifted their price target on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $208.85.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.